Torsten Hoffmann has over 20 years of international R&D leadership experience. For the past 5 years he has served as Chief Operating Officer and Chief Scientific Officer at Silence Therapeutics in Berlin and London, as Chief Scientific Officer and Managing Director at Proteros biostructures in Munich, and before that as Chief Scientific Officer and Executive Vice President at Zealand Pharma in Copenhagen. He previously spent 16 years at Roche in roles of increasing responsibility including Site Head of Medicinal Chemistry at the company head quarters in Switzerland, and Head of the Global Roche Postdoc Fellowship Program. He is the lead inventor of the anti-emetic medicine Netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014.
Torsten holds a PhD in Chemistry from the ETH Zürich, Switzerland, which was followed by a role as research associate at the Scripps Research Institute in La Jolla, California. He has authored more than 90 publications, patent applications and published conference reports. He has served on a number of advisory boards, amongst them on the Corporate Advisory Board of Elsevier, the world's largest scientific publisher in Life Sciences. His awards include the Feodor Lynen award and a fellowship from the Alexander von Humboldt Foundation, Germany.